Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 13 of the 38 sources its claims cite were checked for support.

Brain-targeted drug delivery by manipulating protein corona functions

Open access
Zhang, Zui, Guan, Juan, Jiang, Zhuxuan, Yang, Yang, Liu, Jican, Hua, Wei, Mao, Ying, Li, Cheng, Lu, Weiyue, Qian, Jun, Zhan, Changyou · 2019 · Nature Communications

Abstract

Abstract Protein corona presents a major obstacle to bench-to-bedside translation of targeted drug delivery systems, severely affecting targeting yields and directing unfavorable biodistribution. Corona-mediated targeting provides a new impetus for specific drug delivery by precisely manipulating interaction modes of functional plasma proteins on nano-surface. Here bio-inspired liposomes (SP-sLip) were developed by modifying liposomal surface with a short nontoxic peptide derived from Aβ 1-42 that specifically interacts with the lipid-binding domain of exchangeable apolipoproteins. SP-sLip absorb plasma apolipoproteins A1, E and J, consequently exposing receptor-binding domain of apolipoproteins to achieve brain-targeted delivery. Doxorubicin loaded SP-sLip (SP-sLip/DOX) show significant enhancement of brain distribution and anti-brain cancer effect in comparison to doxorubicin loaded plain liposomes. SP-sLip preserve functions of the absorbed human plasma ApoE, and the corona-mediated targeting strategy works in SP modified PLGA nanoparticles. The present study may pave a new avenue to facilitate clinical translation of targeted drug delivery systems.

Overview

CoChat Summary

TL;DR

The paper reports a corona-mediated brain-targeting strategy in which a short Aβ-derived peptide on liposomes recruits exchangeable apolipoproteins and exposes their receptor-binding domains for BBB transport. In mouse models, the resulting SP-sLip improved brain accumulation and strengthened doxorubicin’s anti-glioma/anti-medulloblastoma efficacy compared with plain liposomes.

Key findings

  • SP-sLip rapidly absorbed apolipoproteins ApoA1, ApoE, and ApoJ; in mouse plasma, the corona showed plateaued binding within 5–30 min, with ApoE binding measured at 2.8 μg ApoE per mg lipid for SP-sLip versus 1.6 μg ApoE per mg lipid for sLip.
  • In vivo, SP-sLip showed higher apolipoprotein content in its protein corona than sLip for all three proteins after intravenous injection, indicating specific absorption occurred in circulation.
  • After plasma preincubation, SP-sLip retained ApoE functionality: it bound 8.4-fold more radiolabeled rhLRP1 than sLip, and SP-sLip enhanced uptake by bEnd.3 cells only when ApoE or mouse plasma was present.
  • Brain delivery and therapy improved substantially: SP-sLip/DOX produced 14.5-fold higher brain doxorubicin distribution than sLip/DOX in healthy BALB/c mice at 4 h (0.93% ID/g vs 0.061% ID/g), increased glioma-region distribution by 45-fold, prolonged median survival in intracranial U87-bearing mice to 50 days versus 33 days with sLip/DOX, and in D425-bearing mice to 29 days versus 25 days with sLip/DOX.

Methods

  • Bio-inspired PEGylated liposomes were prepared with or without a short Aβ-derived peptide (SP), and doxorubicin-loaded formulations were made by ammonium sulfate gradient loading; SP was also tested on PLGA nanoparticles.
  • The study used in vitro ApoE binding assays, plasma protein corona isolation, SDS-PAGE/nano-LC-MS/MS, ELISA, Western blotting, cellular uptake in bEnd.3 cells, and in vivo biodistribution/pharmacodynamics in BALB/c mice, SD rats, and nude mice bearing intracranial U87 or D425 tumors.
  • Main analysis compared corona composition, receptor binding to rhLRP1, brain distribution, survival, and toxicity between SP-sLip, sLip, free DOX, and saline controls using t-tests and log-rank tests.

Limitations

  • The paper does not report a full mechanistic proof that the enhanced brain targeting is exclusively due to ApoE/LRP1, and it notes that intracranial tumor accumulation may be at least partially attributed to LRP1 mediation.
  • It does not state long-term safety, full pharmacology, or clinical outcomes; the evidence is preclinical in mice and rats.
  • The text makes evident that the survival studies use small animal groups (for example, n = 12–13 for U87 and n = 7–9 for D425), which limits precision; this is not stated as a limitation by the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-019-11593-z

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Binding kinetics and capacity of recombinant human ApoE (rhApoE) on liposomal surface. a, b rhApoE and the same amount of BSA mixture in 100 μL PBS was incubated with 100 μL sLip or SP-sLip for 0, 5, 30, 60, 120, and 240 min at 37 °C (rhApoE, 10 μg mL−1; phospholipid, 5 mg mL−1). Protein coronas were obtained by centrifugation at 14k RCF for 20 min, loaded to 4–20% SDS-PAGE gel for separation and stained with silver. The band intensity of absorbed BSA and rhAPOE was calculated by image J software and normalized by setting BSA intensity in the control panel as 100. c, d rhApoE (final concentration of 0, 1, 10, and 50 μg mL−1) and the same amount of BSA mixture in 100 μL PBS was incubated with 100 μL sLip or SP-sLip for 1 h at 37 °C. Protein coronas were obtained as in a. The band intensity of absorbed rhApoE was calculated and normalized by setting that in the 50 μg mL−1 rhApoE panel as 100. Data are means ± SD (n = 3), and analyzed with GraphPad Prism 6.0. **p < 0.01, ***p < 0.001 by student’s t-test
Fig. 1 Binding kinetics and capacity of recombinant human ApoE (rhApoE) on liposomal surface. a, b rhApoE and the same amount of BSA mixture in 100 μL PBS was incubated with 100 μL sLip or SP-sLip for 0, 5, 30, 60, 120, and 240 min at 37 °C (rhApoE, 10 μg mL−1; phospholipid, 5 mg mL−1). Protein coronas were obtained by centrifugation at 14k RCF for 20 min, loaded to 4–20% SDS-PAGE gel for separation and stained with silver. The band intensity of absorbed BSA and rhAPOE was calculated by image J software and normalized by setting BSA intensity in the control panel as 100. c, d rhApoE (final concentration of 0, 1, 10, and 50 μg mL−1) and the same amount of BSA mixture in 100 μL PBS was incubated with 100 μL sLip or SP-sLip for 1 h at 37 °C. Protein coronas were obtained as in a. The band intensity of absorbed rhApoE was calculated and normalized by setting that in the 50 μg mL−1 rhApoE panel as 100. Data are means ± SD (n = 3), and analyzed with GraphPad Prism 6.0. **p < 0.01, ***p < 0.001 by student’s t-testCC BY · PubMed Central
Fig. 2 Characterization of protein coronas in vitro and in vivo. a sLip or SP-sLip were incubated with mouse plasma for 1 h, and the protein coronas were isolated by centrifugation at 14k RCF, separated by SDS-PAGE and stained with silver. b The band intensity of red arrows (ascertained as ApoJ, ApoE, and ApoA1 by nano-LC-MS/MS) was calculated by image J software. The intensity of each apolipoprotein in the formed protein corona on sLip at 0 min was set as 1 for normalization. c, d In vivo absorption of ApoJ, ApoE, and ApoA1 on liposomal surface. DiI-loaded sLip or SP-sLip (100 μL, DiI 0.4 mg mL−1, phospholipid 10 mg mL−1) was injected into BALB/c mice via tail vein. Blood was sampled at 1 h after administration and protein coronas were isolated by centrifugation at 14k RCF. Western Blotting was applied to detect the absorbed ApoJ, ApoE, and ApoA1. Quantitative analysis of proteins was performed by Image J software and the average band intensity of each protein in the formed protein corona on sLip was set as 1 for normalization. Data are means ± SD (n = 3), and analyzed with GraphPad Prism 6.0. *p < 0.05, **p < 0.01, ***p < 0.001 by student’s t-test
Fig. 2 Characterization of protein coronas in vitro and in vivo. a sLip or SP-sLip were incubated with mouse plasma for 1 h, and the protein coronas were isolated by centrifugation at 14k RCF, separated by SDS-PAGE and stained with silver. b The band intensity of red arrows (ascertained as ApoJ, ApoE, and ApoA1 by nano-LC-MS/MS) was calculated by image J software. The intensity of each apolipoprotein in the formed protein corona on sLip at 0 min was set as 1 for normalization. c, d In vivo absorption of ApoJ, ApoE, and ApoA1 on liposomal surface. DiI-loaded sLip or SP-sLip (100 μL, DiI 0.4 mg mL−1, phospholipid 10 mg mL−1) was injected into BALB/c mice via tail vein. Blood was sampled at 1 h after administration and protein coronas were isolated by centrifugation at 14k RCF. Western Blotting was applied to detect the absorbed ApoJ, ApoE, and ApoA1. Quantitative analysis of proteins was performed by Image J software and the average band intensity of each protein in the formed protein corona on sLip was set as 1 for normalization. Data are means ± SD (n = 3), and analyzed with GraphPad Prism 6.0. *p < 0.05, **p < 0.01, ***p < 0.001 by student’s t-testCC BY · PubMed Central
Fig. 3 Characterization of ApoE functions in protein corona. a sLip or SP-sLip (100 μL, 10 mg mL−1 lipid) were incubated with BSA (10 μg mL−1) with or without rhApoE (10 μg mL−1) for 1 h at 37 °C, then recombinant human LRP1 (rhLRP1) was added and incubated for another 1 h at 37 °C. Protein coronas were isolated by centrifugation at 14k RCF, separated by SDS-PAGE and stained with silver. b SP-PEG3400-DSPE dissolved in methanol (0.1 μg per well) was coated in 96-well ELISA plate. After dry in room temperature, it was rinsed by cold PBS for three times. BSA (3%) was used to block for 2 h at room temperature. After thrice PBST rinses, anti-SP antibody (rabbit IgG, containing 0.1% BSA) was added and incubated for 1 h at 37 °C. Different concentrations of free SP (from 0 to 100 μg mL−1) or liposomes (sLip or SP-sLip, 0–5 mg mL−1 lipid) with or without plasma were incubated for another 1 h at 37 °C. HRP-anti-rabbit IgG was applied to detect the primary antibody using TMB kit. c sLip or SP-sLip were incubated with plasma for 1 h at 37 °C, then I125 radiolabeled rhLRP1 was added in the mixture for another 1 h incubation. The radioactivity of liposomes after three cycles centrifugation and rinses was counted for detecting the absorbed rhLRP1. d Microscopic observation of cellular uptake of DiI-loaded sLip (sLip/DiI) or SP-sLip (SP-sLip/DiI) by bEnd.3 cells. sLip/DiI or SP-sLip/DiI was preincubated with PBS, rhApoE (10 μg mL−1) or mouse plasma for 1 h at 37 °C, then incubated with bEnd.3 cells for 4 h at 37 °C. Cellular uptake was detected by confocal laser scanning microscopy. Scale bar = 20 μm. e Quantitative analysis of DiI positive bEnd.3 cells by flow cytometry. Data are means ± SD (n = 3), and analyzed with GraphPad Prism 6.0. ***p < 0.001 by student’s t-test
Fig. 3 Characterization of ApoE functions in protein corona. a sLip or SP-sLip (100 μL, 10 mg mL−1 lipid) were incubated with BSA (10 μg mL−1) with or without rhApoE (10 μg mL−1) for 1 h at 37 °C, then recombinant human LRP1 (rhLRP1) was added and incubated for another 1 h at 37 °C. Protein coronas were isolated by centrifugation at 14k RCF, separated by SDS-PAGE and stained with silver. b SP-PEG3400-DSPE dissolved in methanol (0.1 μg per well) was coated in 96-well ELISA plate. After dry in room temperature, it was rinsed by cold PBS for three times. BSA (3%) was used to block for 2 h at room temperature. After thrice PBST rinses, anti-SP antibody (rabbit IgG, containing 0.1% BSA) was added and incubated for 1 h at 37 °C. Different concentrations of free SP (from 0 to 100 μg mL−1) or liposomes (sLip or SP-sLip, 0–5 mg mL−1 lipid) with or without plasma were incubated for another 1 h at 37 °C. HRP-anti-rabbit IgG was applied to detect the primary antibody using TMB kit. c sLip or SP-sLip were incubated with plasma for 1 h at 37 °C, then I125 radiolabeled rhLRP1 was added in the mixture for another 1 h incubation. The radioactivity of liposomes after three cycles centrifugation and rinses was counted for detecting the absorbed rhLRP1. d Microscopic observation of cellular uptake of DiI-loaded sLip (sLip/DiI) or SP-sLip (SP-sLip/DiI) by bEnd.3 cells. sLip/DiI or SP-sLip/DiI was preincubated with PBS, rhApoE (10 μg mL−1) or mouse plasma for 1 h at 37 °C, then incubated with bEnd.3 cells for 4 h at 37 °C. Cellular uptake was detected by confocal laser scanning microscopy. Scale bar = 20 μm. e Quantitative analysis of DiI positive bEnd.3 cells by flow cytometry. Data are means ± SD (n = 3), and analyzed with GraphPad Prism 6.0. ***p < 0.001 by student’s t-testCC BY · PubMed Central
Fig. 4 Biodistribution of sLip and SP-sLip in healthy BALB/c mice. a DiI-labeled sLip (sLip/DiI) and SP-sLip (SP-sLip/DiI) were injected via tail vein and brains were dissected and sectioned at 4 h after administration. Brain slices were stained with anti-CD31 antibody (green) and biodistribution of liposomes (red) in hippocampus (Hippo) and cortex were observed by confocal laser scanning microscopy. Scale bar = 20 μm. Doxorubicin distribution in brain (b) and other main organs (c) at 1 h, 4 h, and 24 h after intravenous injection of SP-sLip/DOX and sLip/DOX. Data are means ± SD (n = 3–5). *p < 0.05, **p < 0.01 by student’s t-test
Fig. 4 Biodistribution of sLip and SP-sLip in healthy BALB/c mice. a DiI-labeled sLip (sLip/DiI) and SP-sLip (SP-sLip/DiI) were injected via tail vein and brains were dissected and sectioned at 4 h after administration. Brain slices were stained with anti-CD31 antibody (green) and biodistribution of liposomes (red) in hippocampus (Hippo) and cortex were observed by confocal laser scanning microscopy. Scale bar = 20 μm. Doxorubicin distribution in brain (b) and other main organs (c) at 1 h, 4 h, and 24 h after intravenous injection of SP-sLip/DOX and sLip/DOX. Data are means ± SD (n = 3–5). *p < 0.05, **p < 0.01 by student’s t-testCC BY · PubMed Central
Fig. 5 Biodistribution of sLip and SP-sLip in intracranial glioma. DiI-labeled sLip (sLip/DiI) and SP-sLip (SP-sLip/DiI) were injected via tail vein of nude mice bearing intracranial glioma (at day 16 after implantation). Mouse brains were dissected and sectioned at 4 h after administration. Brain slices were stained with anti-CD31 antibody (green) and biodistribution of liposomes (red) in normal brain tissues (labeled with Brain) and glioma region (labeled with Glioma) were observed by confocal laser scanning microscopy and quantified by Image Pro. Scale bar = 20 μm. Data are means ± SD (n = 3). ***p < 0.001 by student’s t-test
Fig. 5 Biodistribution of sLip and SP-sLip in intracranial glioma. DiI-labeled sLip (sLip/DiI) and SP-sLip (SP-sLip/DiI) were injected via tail vein of nude mice bearing intracranial glioma (at day 16 after implantation). Mouse brains were dissected and sectioned at 4 h after administration. Brain slices were stained with anti-CD31 antibody (green) and biodistribution of liposomes (red) in normal brain tissues (labeled with Brain) and glioma region (labeled with Glioma) were observed by confocal laser scanning microscopy and quantified by Image Pro. Scale bar = 20 μm. Data are means ± SD (n = 3). ***p < 0.001 by student’s t-testCC BY · PubMed Central
Fig. 6 Kaplan–Meier survival curve of nude mice bearing intracranial brain cancer cells after treatments. For mouse bearing U87 cells (a), saline (27 days, n = 12), DOX (31 days, n = 13), sLip/DOX (33 days, n = 13), and SP-sLip/DOX (50 days, n = 13) were intravenously administered at a total DOX dose of 10 mg kg−1 (injections at day 7, 9, 11, 13, and 15 after U87 cells implantation). For mouse bearing D425 (b), saline (22 days, n = 8), DOX (23.5 days, n = 8), sLip/DOX (25 days, n = 7), and SP-sLip/DOX (29 days, n = 9) were intravenously administered at a total DOX dose of 12 mg kg−1 (injections at day 3, 5, 7, 10, 12, and 14 days after D425 cells implantation). Data were plotted and the median survival time was calculated using GraphPad Prism 6.0 (Log-rank (Mantel–Cox) test)
Fig. 6 Kaplan–Meier survival curve of nude mice bearing intracranial brain cancer cells after treatments. For mouse bearing U87 cells (a), saline (27 days, n = 12), DOX (31 days, n = 13), sLip/DOX (33 days, n = 13), and SP-sLip/DOX (50 days, n = 13) were intravenously administered at a total DOX dose of 10 mg kg−1 (injections at day 7, 9, 11, 13, and 15 after U87 cells implantation). For mouse bearing D425 (b), saline (22 days, n = 8), DOX (23.5 days, n = 8), sLip/DOX (25 days, n = 7), and SP-sLip/DOX (29 days, n = 9) were intravenously administered at a total DOX dose of 12 mg kg−1 (injections at day 3, 5, 7, 10, 12, and 14 days after D425 cells implantation). Data were plotted and the median survival time was calculated using GraphPad Prism 6.0 (Log-rank (Mantel–Cox) test)CC BY · PubMed Central
Fig. 7 Evaluation of immunocompatibility of SP-sLip. a Immune response caused by sLip or SP-sLip in C57BL/6 mice. Absorbance in the ELISA plate versus serum dilution and antibody titer reported as log (EC50). mPEG2000-DSPE and SP-PEG3400-DSPE were used as antigens for sLip and SP-sLip, respectively. Data are means ± SD (n = 5). b Pharmacokinetic profile of DiI-labeled sLip and SP-sLip in SD rats over 24 h after intravenous injection. Data are means ± SD (n = 4) c PK parameters are calculated by DAS 2.0, and titration of IgG and IgM was calculated using GraphPad Prism 6.0. **p < 0.01 by student’s t-test
Fig. 7 Evaluation of immunocompatibility of SP-sLip. a Immune response caused by sLip or SP-sLip in C57BL/6 mice. Absorbance in the ELISA plate versus serum dilution and antibody titer reported as log (EC50). mPEG2000-DSPE and SP-PEG3400-DSPE were used as antigens for sLip and SP-sLip, respectively. Data are means ± SD (n = 5). b Pharmacokinetic profile of DiI-labeled sLip and SP-sLip in SD rats over 24 h after intravenous injection. Data are means ± SD (n = 4) c PK parameters are calculated by DAS 2.0, and titration of IgG and IgM was calculated using GraphPad Prism 6.0. **p < 0.01 by student’s t-testCC BY · PubMed Central
Fig. 8 Characterization of ApoE function in protein corona formed in human plasma. sLip and SP-sLip (a), or plain PLGA nanoparticles (PLGA NP) and SP-modified PLGA nanoparticles (SP-PLGA NP) (b) were incubated with human plasma for 1 h at 37 °C, then I125 radiolabeled rhLRP1 was added in the mixture for another 1 h incubation. The radioactivity of liposomes and PLGA nanoparticles after three cycles centrifugation and rinses was counted for detecting the absorbed rhLRP1. Data are means ± SD (n = 4), **p < 0.01, ***p < 0.001 by student’s t-test
Fig. 8 Characterization of ApoE function in protein corona formed in human plasma. sLip and SP-sLip (a), or plain PLGA nanoparticles (PLGA NP) and SP-modified PLGA nanoparticles (SP-PLGA NP) (b) were incubated with human plasma for 1 h at 37 °C, then I125 radiolabeled rhLRP1 was added in the mixture for another 1 h incubation. The radioactivity of liposomes and PLGA nanoparticles after three cycles centrifugation and rinses was counted for detecting the absorbed rhLRP1. Data are means ± SD (n = 4), **p < 0.01, ***p < 0.001 by student’s t-testCC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 1 Not valid · 8 Not checked · 53 Own results and interpretations

39 more claims

Create a free account to see all 69 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 15
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 62 references

Cited by

See all 334

Metadata

Authors
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., & Zhan, C.
Affiliations
Fudan University (CN)
Corresponding author
Zhan, Changyou
Venue
Nature Communications
Published
2019-08-08
Volume
10
Issue
1
Pages
3561-3561
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2968488780
Cited by
334
References
62
Citations by year
2026: 30 · 2025: 59 · 2024: 61 · 2023: 56 · 2022: 49 · 2021: 38 · 2020: 36 · 2019: 4
FWCI
8.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • China Postdoctoral Science Foundation (2017M610229)
  • Shanghai Education Development Foundation (2017-01-07-00-07-E00052)
  • Shanghai Municipal Health Bureau (2018BR04)
  • Natural Science Foundation of Shanghai (18ZR1404800)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
protein corona, brain drug delivery, amyloid-beta, apolipoprotein E, apolipoprotein A-I, clusterin, plasma protein binding, doxorubicin, PLGA nanoparticles, brain cancer, tissue distribution
MeSH terms
Protein Corona, Animals, Apolipoproteins E, Brain, Brain Neoplasms, Doxorubicin, Humans, Liposomes, Male, Peptide Fragments, Tissue Distribution, Amyloid beta-Peptides, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Rats, Nanoparticles, Protein Interaction Domains and Motifs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brain-targeted drug delivery by manipulating protein corona functions. https://app.cochat.ai/papers/10.1038/s41467-019-11593-z
The paper
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., & Zhan, C. (2019). Brain-targeted drug delivery by manipulating protein corona functions. Nature Communications. https://doi.org/10.1038/s41467-019-11593-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.